Continuing Medical Education
Accreditation Statement
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
Credit Designation Statement
AACR has designated this live activity for a maximum of 16.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
Claiming (CME) Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by Wednesday, March 19, 2025. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 16.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive ABIM MOC, participants must request MOC in the CME Request for Credit Survey and complete all questions. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.
Statement of Educational Need, Target Audience, and Learning Objectives
There are few generalities in cancer research which apply to all tumors. However, it can be unequivocally stated that all of the more than 20,000 human tumors that have been examined in the TCGA project contain alterations in DNA methylation patterns. Understanding the causation for these changes, their relevance to the cancer phenotype and their suitability as targets for therapy is obviously important. Studies and meetings on this subject tend to focus on its role as part of a cascade involving chromatin modifications, etc. This conference will have a sharp focus on mechanisms of normal and abnormal DNA methylation, its role in chronic pre-leukemic conditions, their function in altering the epigenome, and also the targetability of DNA methylation as a therapeutic strategy. It will also highlight the effects of DNA methylation on immune cell function.
The fields of DNA methylation and epigenetics have expanded dramatically over the last few years. The goal of this conference is to educate structural biologists, biochemists, biologists, immunologists, cancer biologists and drug development teams on the overall picture providing great depth in specific areas, yet giving an overall view of the current state of the field. The AACR has played a major role in the development and realization of the importance of epigenetics in cancer and this meeting will give participants an idea of the totality of the field at the same time as providing great depth so that the concepts can be fully developed.
The potential attendance is expected to be quite large given that the topics will interest structural biologists, cellular biologists, genomicists, drug companies, graduate students and postdocs who will get a focused view of the state of one of the most exciting areas in cancer research today.
After participating in this CME activity, physicians should be able to:
- Articulate the rapid evolution of DNA Methylation as a field of interest in cancer
- Identify the role of DNA methylation in altering the epigenome in certain cancer type
- Formulate strategies for the development of cancer interception approaches.
- Assess the state-of-the-art tools available for using circulating DNA methylation markers for early cancer detection.
Disclosure Statement
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed all financial relationships they have with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products or services used by or on patients. All of the relevant financial relationships for these individuals have been mitigated
Planner and Speaker Financial Disclosure Index Available Soon
Acknowledgment of Financial or Other Support
This activity is supported by Professional Educational Grants which will be disclosed at the activity.
Questions about CME?
Please read our frequently asked questions. If you still have questions contact the Office of CME at (215) 440-9300 or [email protected].